| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00972322 | Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012) | PHASE1 | COMPLETED | 56 | — | — | Aug 24, 2009 | Jan 26, 2010 | Sep 10, 2018 | - | — |
The 24-hour WMG is derived from multiple glucose values collected during both fasting and post-meal periods. A "weighted" rather than a "simple" mean is used to avoid overrepresentation of post-meal glucose values. Blood samples for glucose were collected immediately prior to, and after each meal, and overnight and fasting one hour pre-dose.
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. A serious AE is any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Arm | Type | Description |
|---|---|---|
| MK-8245 50 mg | EXPERIMENTAL | MK-8245, 50 mg, twice daily for 28 days |
| Placebo | PLACEBO_COMPARATOR | Placebo to MK-8245, 50 mg, twice daily |
| Name | Type | Description |
|---|---|---|
| MK-8245 | DRUG | MK-8245 50 mg twice daily for 28 days |
| Comparator: placebo | DRUG | matching placebo to MK-8245 twice daily for 28 days |
Inclusion Criteria: * Subject has a diagnosis of type 2 diabetes and is being treated with diet and exercise alone, a single oral anti-hyperglycemic agent or a combination of two oral anti-hyperglycemic agents * Subject is willing to follow a weight-maintaining diet and exercise program during the ...